#USA #NASDAQ #Cambridge, Massachusetts #Decoy Therapeutics #Minimum Bid

Decoy Therapeutics Regains Nasdaq Compliance

Decoy Therapeutics, Inc. (NASDAQ: DCOY) has announced a significant milestone in its journey as a biotechnology firm. As of March 31, 2026, it received formal notification from Nasdaq Stock Market LLC confirming that it has regained compliance with the Minimum Bid Price Requirement set forth in Listing Rule 5550(a)(2). This development is crucial for Decoy, as it maintains its standing on The Nasdaq Capital Market, thereby allowing the company to continue trading its securities without interruption.

Background on Compliance Requirements

The Minimum Bid Price Requirement is a critical condition for companies listed on Nasdaq, which mandates that a stock's bid price must remain above a certain threshold. Falling below this minimum can trigger compliance reviews and potentially lead to delisting if not rectified in a reasonable time frame. By regaining compliance, Decoy can focus on its strategic objectives without the uncertainty that accompanies delisting risks.

Nasdaq also informed Decoy that it would be under a Mandatory Panel Monitor for one year from the compliance date. This monitoring means that any future deviations from the Minimum Bid Price Requirement during this period could lead to another compliance review. In the event of noncompliance, the company will be able to request a hearing with the Nasdaq Hearings Panel,
ensuring they have a chance to present their case.

CEO's Statement

In a statement, the CEO of Decoy Therapeutics expressed satisfaction with the company's ability to meet Nasdaq's requirements, emphasizing that the firm is poised to leverage new opportunities in the biotech sector. The CEO also acknowledged the challenges faced and thanked the team's dedication in navigating these hurdles, focusing on the importance of regulatory compliance in affirming investor confidence.

Forward-Looking Statements

This announcement comes alongside several ambitious goals that Decoy has set for its product development pipeline. The company aims to reach key milestones with its leading assets in the near future, which may significantly affect its stock performance and market perception. However, the forward-looking statements presented in the release contain certain risks and uncertainties.

These include the potential of not acquiring the necessary financing to fulfill their business plans or encountering unexpected setbacks in product development or regulatory processes, particularly as it relates to the ongoing IND (Investigational New Drug) application processes.

Conclusion

Decoy Therapeutics is now in a critical phase of its evolution as it navigates through this mandatory monitoring while working diligently to hit forthcoming milestones. As it fortifies its compliance with federal regulations, stakeholders will be keeping a close watch on how this affects the company's market strategies and future endeavors.

Investors and industry observers are encouraged to stay updated with Decoy's filings and press releases as it works to sustain its compliance and the ambitions of bringing innovative therapeutics to the market.